Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Joshua C, Curtin"'
Autor:
Santiago Viteri, Anna Minchom, Lyudmila Bazhenova, Sai‐Hong Ignatius Ou, Joshua M. Bauml, Scott A. Shell, Michael Schaffer, Junchen Gu, Jennifer B. Rose, Joshua C. Curtin, Parthiv Mahadevia, Nicolas Girard
Publikováno v:
Molecular Oncology, Vol 17, Iss 2, Pp 230-237 (2023)
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) account for ≤ 12% of all EGFR‐mutant nonsmall cell lung cancers. We analysed real‐world datasets to determine the frequency of ex20ins variants, and the ability of po
Externí odkaz:
https://doaj.org/article/c4da93c6b1ad420a85fa00e6dd68825d
Autor:
Keunchil Park, Joshua K. Sabari, Eric B. Haura, Catherine A. Shu, Alexander Spira, Ravi Salgia, Karen L. Reckamp, Rachel E. Sanborn, Ramaswamy Govindan, Joshua M. Bauml, Joshua C. Curtin, John Xie, Amy Roshak, Patricia Lorenzini, Dawn Millington, Meena Thayu, Roland E. Knoblauch, Byoung Chul Cho
Publikováno v:
Lung Cancer. 178:166-171
Autor:
Santiago Viteri, Anna Minchom, Lyudmila Bazhenova, Sai‐Hong Ignatius Ou, Joshua M. Bauml, Scott A. Shell, Michael Schaffer, Junchen Gu, Jennifer B. Rose, Joshua C. Curtin, Parthiv Mahadevia, Nicolas Girard
Publikováno v:
Molecular oncology, vol 17, iss 2
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) account for ≤ 12% of all EGFR-mutant nonsmall cell lung cancers. We analysed real-world datasets to determine the frequency of ex20ins variants, and the ability of polyme
Autor:
null Santiago Viteri, null Anna Minchom, null Lyudmila Bazhenova, null Sai‐Hong Ignatius Ou, null Joshua M. Bauml, null Scott A. Shell, null Michael Schaffer, null Junchen Gu, null Jennifer B. Rose, null Joshua C. Curtin, null Parthiv Mahadevia, null Nicolas Girard
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d098ce579c8c2b3d83fd82c8d91600c
https://doi.org/10.1002/1878-0261.13327/v2/response1
https://doi.org/10.1002/1878-0261.13327/v2/response1
Autor:
Rachel E. Sanborn, Saiama N. Waqar, Byoung Chul Cho, Benjamin Besse, Koichi Goto, Yongsheng Wang, Se-Hoon Lee, Melina E. Marmarelis, Yuichiro Ohe, Dong-Wan Kim, Antonio Calles, Joel Neal, Christina S. Baik, Pasi A. Janne, Joshua C. Curtin, Bharvin Patel, Mike Gormley, S. Martin Shreeve, Joshua M. Bauml, Roland E. Knoblauch, James Chih-Hsin Yang
Publikováno v:
Cancer Research. 83:2166-2166
Background: Among post-osimertinib (osi), chemotherapy-naïve patients (pts) treated with amivantamab (ami) and lazertinib (laz) in CHRYSALIS Cohort E, NGS of baseline ctDNA and tumor tissue revealed pts with identified EGFR/MET-based resistance (eg,
Autor:
Chaitanya Parmar, Oscar M. Carrasco-Zevallos, Joshua C. Curtin, Darshana Govind, Bing Xia, S. Martin Shreeve, Songbai Wang, Timothy Jatkoe, Patricia Raciti, Levon Demirdjian, Joel Greshock, Kristopher Standish, Stephen S.F. Yip
Publikováno v:
Cancer Research. 83:6554-6554
Objective: DNA amplifications of the cMET locus (METamp) are rare (1-6%) in non-small cell lung cancer (NSCLC). The ability to efficiently identify patients with METamp could accelerate development of cMET-targeting therapies by identifying patients
Autor:
Timothy Jatkoe, Songbai Wang, Justin I. Odegaard, Anne Marie Velasco Roth, Drew Osgood, Gabriela Martinez, Paul Lucas, Joshua C. Curtin, Jayaprakash Karkera
Publikováno v:
The Journal of molecular diagnostics : JMD. 24(11)
Amivantamab, an epidermal growth factor receptor (EGFR)-c-Met bispecific antibody, targets activating/resistance EGFR mutations and MET mutations/amplifications. In the ongoing CHRYSALIS study (ClinicalTrials.gov Identifier: NCT02609776), amivantamab
Autor:
Keunchil Park, Joshua Sabari, Eric B. Haura, Catherine A. Shu, Alexander Spira, Ravi Salgia, Karen L. Reckamp, Rachel E. Sanborn, Ramaswamy Govindan, Joshua M. Bauml, Joshua C. Curtin, John Xie, Amy Roshak, Patricia Lorenzini, Dawn Millington, Meena Thayu, Roland E. Knoblauch, Byoung Chul Cho
Publikováno v:
Annals of Oncology. 33:S482
Autor:
Catherine A. Shu, Koichi Goto, Yuichiro Ohe, Benjamin Besse, Se-Hoon Lee, Yongsheng Wang, Frank Griesinger, James Chih-Hsin Yang, Enriqueta Felip, Rachel E. Sanborn, Reyes Bernabe Caro, Joshua C Curtin, Jun Chen, Janine M. Mahoney, Leonardo Trani, Joshua Michael Bauml, Roland Elmar Knoblauch, Meena Thayu, Byoung Chul Cho
Publikováno v:
Journal of Clinical Oncology. 40:9006-9006
9006 Background: Initial results with the amivantamab (ami) and lazertinib (laz) regimen showed encouraging efficacy in patients (pts) whose disease progressed after standard-of-care osimertinib (osi) and platinum-based chemotherapy (pt-chemo; Shu An
Autor:
Matthew Krebs, Alexander I. Spira, Byoung Chul Cho, Benjamin Besse, Jonathan W. Goldman, Pasi A. Janne, Zhiyong Ma, Aaron Scott Mansfield, Anna Rachel Minchom, Sai-Hong Ignatius Ou, Ravi Salgia, Zhijie Wang, Casilda Llacer Perez, Grace Gao, Joshua C Curtin, Amy Roshak, Robert W. Schnepp, Meena Thayu, Roland Knoblauch, Chee Khoon Lee
Publikováno v:
Journal of Clinical Oncology. 40:9008-9008
9008 Background: Amivantamab, a fully human bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET, is approved for the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion after prior platinum-based chem